ITGR

Business Context and Reporting Period

Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2006
Business Overview: Greatbatch designs and manufactures critical components for implantable medical devices (IMC segment) and high-performance batteries for commercial applications like oil and gas exploration (ECP segment). The company operates two reportable segments: Implantable Medical Components and Electrochem Commercial Power.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 21% to $68.1 million, driven by a 20% increase in the IMC segment (strong demand for ICD batteries and feedthroughs) and a 24% increase in the ECP segment (growth in oil and gas and oceanographic markets).
• Profitability: Net income rose 66% to $6.7 million. Operating margin improved by 3.7 percentage points to 14.8%, aided by production efficiencies and higher sales volume.
• Accounting Change: The company adopted SFAS No. 123(R) on January 1, 2006, requiring the expensing of stock-based compensation. This resulted in an incremental cost of approximately $0.9 million ($0.03 per diluted share) for the quarter.
• Cash Flow: Operating cash flow turned negative ($3.6 million used) compared to positive cash flow ($2.9 million provided) in the prior year. This was primarily due to a $9.9 million increase in accounts receivable and a $10.0 million decrease in accrued expenses (payments for 2005 incentive compensation).
• Restructuring Costs: Other operating expenses included $2.7 million in charges related to facility consolidations (Alden, Carson City, Columbia) and shutdowns, compared to $2.4 million in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management expects operating margins to remain strong due to operating leverage and facility consolidation. Capital spending for 2006 is projected between $22.0 million and $27.0 million, with $5.0 to $7.0 million allocated to the Tijuana Facility build-out.
• Future Expenses: Other operating expenses for the remainder of 2006 are expected to range from $8.0 million to $10.0 million, primarily related to ongoing plant consolidations. These expenses are expected to be substantially reduced after the second quarter of 2007.
• Tax Rate: The effective tax rate is estimated to be approximately 34% for the full year 2006.
• Risks and Contingencies:
  • Customer Concentration: Three customers (Guidant, St. Jude Medical, and Medtronic) accounted for approximately 70% of total sales in Q1 2006.
  • Legal Proceedings: A former non-medical customer alleges misuse of proprietary information; the potential risk of loss is estimated between $0 and $1.7 million.
  • Consolidation Execution: Risks associated with the completion of facility moves to Alden, NY, and Tijuana, Mexico, including potential production inefficiencies.

Investor Verification Checklist

• Customer Concentration: Verify the stability of relationships with the top three customers representing 70% of revenue.
• Operating Cash Flow: Monitor the reversal of the negative operating cash flow trend, specifically the management of accounts receivable growth relative to sales.
• Restructuring Completion: Track the progress and cost realization of the facility consolidations in Alden, Carson City, and Columbia to ensure projected savings ($7.5M - $9.1M annually) are achieved.
• Stock-Based Compensation: Assess the ongoing impact of SFAS No. 123(R) on future earnings, noting $7.5 million of unrecognized compensation cost remaining.
• Debt Covenants: Confirm continued compliance with the EBITDA to Fixed Charges and Leverage ratio covenants under the $50 million revolving credit facility.